Huge heterogeneity of patient characteristics, treatment patterns, hospital costs exists in non-small cell lung cancer surgeries among different centers of China: A study of 5060 patients based on the Chinese national NSCLC outcome registry.
Jian Zhou(Xuzhou Medical College), Jun Wang(Peking University), Fan Yang(Peking University People's Hospital), Chenlong Xu(Shandong Tumor Hospital), Yong‐Zhen Zhang(Shanghai Public Health Clinical Center), Xianzhen Liao(Hunan Cancer Hospital), Naiquan Mao(Tumor Hospital of Guangxi Medical University), Xun Wang(Peking University), Junfeng Liu(Hebei Medical University), Hao Li(Peking University), Yin Li(Hebei Medical University), Lin Xu(Guangdong Pharmaceutical University), Xiaotao Zhang(The University of Texas MD Anderson Cancer Center), Lin Zhu, Yunchao Huang(North China University of Water Resources and Electric Power), Yanguo Liu(Peking University), Changjun He(Harbin Medical University), Lingbin Du(Shandong University), Hui Qiu(Chongqing Cancer Hospital), Aaron Jin(Liaoning Cancer Hospital & Institute)
Cited by 0
Related Papers
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials
|The Lancet Oncology|2015|1.6k
Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response
|Science|2021|876
Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial
|The Lancet Respiratory Medicine|2020|508